Walgreens Didn't Die at the Pharmacy Counter. It Died Buying Doctors' Offices.

On August 28, 2025, Walgreens stopped being a public company - and then, on that same day, it stopped being a single company at all. The buyer, Sycamore Partners, did not take it private to fix it. It took it private to take it apart, carving the entity into five standalone businesses before the ink was dry: Walgreens, The Boots Group, Shields Health Solutions, CareCentrix, and VillageMD.⁵ A name that had stood in the Dow for years — until Amazon replaced it in February 2024 — walked off the public market and immediately fell into pieces.⁹ The breakup wasn't the cleanup after the fall. The breakup was the point.

The official story is that the corner drugstore lost a slow war to Amazon, Costco, and your phone - that retail pharmacy simply got commoditized. The pharmacy counter killed Walgreens. That isn't where the body is. Walgreens didn't die ringing up shampoo and flu shots. It died buying doctors' offices.

The $12.4 billion that vanished from one bet

For most of a decade, Walgreens told investors it was no longer a retailer - it was becoming a healthcare company. The flagship of that thesis was VillageMD, a chain of primary-care clinics it poured billions into, the idea being that you'd see a doctor and fill the prescription under the same roof. Then, in the second quarter of fiscal 2024, the company looked at what VillageMD was actually worth and wrote down its goodwill by $12.4 billion in a single non-cash charge - a $5.8 billion after-tax hit that turned that quarter into a $5.9 billion net loss, against $703 million of net earnings a year earlier.³ That is not the sound of a business underperforming a plan. That is the sound of a company admitting, in the flat language of an accounting charge, that the plan was never worth what it paid.

By the time the full year closed, the damage had compounded into a $14.1 billion operating loss and a loss of $10.01 per share, up more than 180% from the prior year's loss; the fourth quarter alone swung to a $3.0 billion net loss from a $180 million loss the year before.¹ You can see it written directly on the balance sheet: goodwill fell from $28.2 billion to $15.5 billion in twelve months.² Goodwill is the accounting word for the premium you paid above hard assets - the dollars you spent on a story. Nearly thirteen billion of that story evaporated in a year. Here is the thesis plainly: Walgreens didn't fall because its stores stopped working. It fell because the thing it bought to replace its stores never worked, and the public market priced in that gap with brutal speed.

Three weights on one balance sheet

The write-down didn't land on a healthy company. It landed on one already carrying two other weights. The first was legal: in April 2025 the Justice Department, DEA, and HHS-OIG announced a base settlement of $300 million - with a further $50 million owed if the company was sold, merged, or transferred before fiscal 2032 - to resolve allegations that Walgreens had illegally filled millions of invalid opioid and controlled-substance prescriptions over roughly a decade.⁷ Read that contingency carefully, because it became self-executing: by selling to Sycamore, Walgreens tripped the very trigger that converts $300 million into $350 million. The second weight was operational. In October 2024 the company announced it would close roughly 1,200 underperforming U.S. stores over about three years, some 500 of them in fiscal 2025, out of a base of roughly 8,500 to 8,700 locations.⁶ Closing one in seven of your own stores is not a strategy. It is triage.

Any one of these - the failed pivot, the opioid liability, the chronic squeeze on pharmacy reimbursement that shrinks the margin on every script filled - is survivable. Stacked together, they did something specific and fatal to a public company: they made the balance sheet uninvestable. A public equity needs a story a shareholder can buy into. Walgreens' story had become a list of liabilities with a shrinking store count attached, and the stock told the truth - it closed at $8.85 on December 9, 2024, a fraction of its former self.⁴

Wasn't this just a cheap buyout of a busted retailer?

The fair objection is that this is the ordinary fate of a tired retailer: a private-equity firm scoops up a fading chain cheaply, and the press dutifully calls it a '$10 billion buyout.' But that framing misreads the deal in two ways. First, on price: $11.45 per share in cash was a 29% premium to that December close, and the company's own filing put the total transaction value - debt and a contingent VillageMD payout of up to $3.00 per share included - at up to $23.7 billion.⁴ This was not a bargain-bin grab. Second, and more telling, is what Sycamore did with it. A buyer betting on a retail turnaround keeps the chain whole and fixes the stores. Sycamore instead split the company into five on day one.⁵ That move only makes sense if the conglomerate itself was the problem - if the parts were worth more apart than the whole was together. The breakup-by-design is the verdict: the 'healthcare-plus-retail-plus-Boots-plus-clinics' thesis didn't just underperform, it destroyed value by being bundled. Shareholders agreed, voting to approve the sale by 96%, including 95% of unaffiliated holders.⁸ When the owners of a business vote almost unanimously to dismantle it, the market has rendered its judgment.

There is a tidy irony at the center of the fall. Walgreens spent the better part of a decade trying to stop being a drugstore - reaching for primary care, for clinics, for the higher-margin promise of owning a slice of healthcare itself. The pivot it chose to escape the squeezed retail business is precisely what broke it; the $12.4 billion it lost on VillageMD dwarfs anything a slow quarter at the pharmacy counter could ever have cost. The corner store, it turned out, was the steady part. The reinvention was the gamble. And when Sycamore finally carved the company into five, it was simply finishing what the impairment had already proved: the pieces had never belonged together in the first place. Walgreens didn't fall because the world stopped needing a pharmacy. It fell because it bet that being a pharmacy wasn't enough - and the bet was the one thing it couldn't afford to lose.